Pongracz, Active Wnt/β-catenin signaling is re- quired for embryonic thymic epithelial development and functionality ex vivo, Immunobiology 219 (2014) 644-652.Kvell, K., Fejes, A. V., Parnell, S. M. and Pongracz, J. E. (2014). Active Wnt/beta-catenin signaling is required for ...
Non-phospho-4E-BP1 (Thr46) (87D12) Rabbit mAb价格:价格电议产品详情:温馨提示:优宁维所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)! ... 纯度:见优宁维官网% 包装规格:见优宁维官网 用途:详见说明书 ...
Pongracz, Active Wnt/β-catenin signaling is re- quired for embryonic thymic epithelial development and functionality ex vivo, Immunobiology 219 (2014) 644-652.Kvell, K., Fejes, A. V., Parnell, S. M. and Pongracz, J. E. (2014). Active Wnt/beta-catenin signaling is required for ...
Down-regulation of beta-catenin led to a marked reduction in both the total protein level and the activated/phosphorylated form of STAT3, another signaling protein previously shown to be important in the pathogenesis of ALK-positive anaplastic large cell lymphoma. In contrast to some of the ...
Anand M, Lai R, Gelebart P (2011) {beta}-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 96:253–261Anand M, Lai R, Gelebart P (2011) beta-catenin is constitutively active and ...
Amidi, F. Akbari-Asbagh et al., "The Wnt/β- catenin signaling in endometriosis, the expression of total and active forms of β-catenin, total and inactive forms of gly- cogen synthase kinase-3β, WNT7a and DICKKOPF-1," European Journal of Obstetrics & Gynecology and Reproduc- tive ...
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999; 18: 3054±3063.Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Leal JF, Zhurinsky J, Geiger B, Oren M (1999) Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 18: ...
The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that ...
The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that ...
Pongracz, Active Wnt/β-catenin signaling is re- quired for embryonic thymic epithelial development and functionality ex vivo, Immunobiology 219 (2014) 644-652.Kvell, K., Fejes, A. V., Parnell, S. M. and Pongracz, J. E. (2014). Active Wnt/beta-catenin signaling is required for ...